

For, PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

 Filing Date
 Group Art Unit

 Sheet
 1
 OF
 17
 December 30, 2003
 1645 / 632

		U.S.	Patent Documen	ts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Ui;	3,972,859 Aug 3, 1976		Fujino et al.			
-1	3,992,365	Nov 16, 1976	Beddell et al.			_
	4,003,884	Jan 18, 1977	Konig et al.			
	4,005,063	Jan 25, 1977	Gendrich et al.			
	4,008,209	Feb 15, 1977	Fujino et al.			
	4,010,125	Mar 1, 1977	Schally et al.			
	4,010,149	Mar 1, 1977	Baba et al.			
U	4,018,726	Apr 19, 1977	Schally et al.			

Foreign Patent Documents							
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER	5/12		OBAGO	00000000	YES	NO
OM	76177/91	Nov 19, 1992	Australia				
	56394/94	Sep 1, 1994	Australia				
	181236	May 14, 1986	Europe				
	217659	Apr 8, 1987	Europe				
	364819	Apr 25, 1990	Europe				

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
01	A1	Aboudkhil et al., (1991) Scand. J. Immunol. 34, 647-653
1	A2	Akashi et al., (1997) Cell 89(7) 1033-1041
•	А3	Ali et al., (2000) Transplantation 69:221
	A4	Alpdogan et al., (2001) Blood 98:2256
	A5	Amado et al., (1999) Front. Biosci. 4:D468-475
	A7	Andersen, (1994) Infect. Immunity, 62:2536
	/ A8	Andrew et al., (2002) Exp. Gerontol. 37:455
V	A9	Andrew, D. and Aspinall, R., (2001) J. Immunol. 166(3): 1524-1530

EXAMINER //	DATE CONSIDERED
Valto	8/10/07
EVAMINED. International and the state of the	

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

2 OF 17 December 30, 2003

Group Art Unit 1645/632

		U.S. F	Patent Documer	nts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Op	4,024,121	May 17, 1977	Schally et al.			
	4,089,946	May 16, 1978	Foell et al.	, "		
	4,100,274	Jul 11, 1978	Dutta et al.			
	4,118,483	Oct 3, 1978	Konig et al.			
	4,128,638	Dec 5, 1978	Moody			
	4,218,439	Aug 19, 1980	Rivier et al.			
	4,234,571	Nov 18, 1980	Nestor et al.			
	4,275,001	Jun 23, 1981	Konig et al.			

Foreign Patent Documents								
EXAMINER D	DOCUMENT DATE	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
INITIAL	NUMBER	DAIL .	00011111	05.00	SOBOLAGO	YES	NO	
01	413209	Feb 20, 1991	Europe					
	7923545	Sep 21, 1979	France					
	2509783	Sep 11, 1975	Germany					
	9112825	Jul 31, 1991	Great Britain					
\overline{V}	9112859	Jul 31, 1991	Great Britain					

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
OA	A10	Aspinall, et al., (2000) Vaccine 18:1629
	A11	Aspinall, R., (1997) <i>J. Immunol.</i> 158:3037
	A12	Atassi et al., (2001) Crit. Rev. Immunol. 21:1
	A13	Atlan-Gepner, C., Naspetti, M., et al., (1999) Autoimmunity 3:249-260
	A14	Bach (1983) Birth Defects Original Article Ser. 19(3): 245-253
	A15	Bahnson <i>et al.</i> , (1997) "Method for Retrovirus-Mediated Gene Transfer to CD34+- Enriched Cells," in <u>Gene Therapy Protocol</u> s (P.D. Robbins, ed.), Humana Press, pp.249-263
V	A16	Banerjee et al., (1994) Stem Cells 12:378

EXAMINER / 12	DATE CONSIDERED
Voue A	8/10/07
EXAMINER: Initial if citation is considered	whether or not citation is in conformance with MPEP &

609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

3

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

		U.S. I	Patent Documer	nts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Dn	4,490,291	Dec 25, 1984	Fujino			
7	4,608,251	Aug 26, 1986	Mia			
	4,642,332	Feb 10, 1987	Folkers et al.			
	4,656,247	Apr 7, 1987	Folkers et al.			
	4,775,361	Oct 4, 1988	Jacques et al.			
	4,866,160	Sep 12, 1989	Coy et al.			
	4,992,421	Feb 12, 1991	De et al.			
- 1//	5,003,011	Mar 26, 1991	Coy et al.			

Foreign Patent Documents									
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
INITIAL	NUMBER	DATE	COUNTAI	CEASS	SUBCLASS	YES	NO		
01	WO 88/01176	Feb 25, 1988	wo		}				
	W.O 92/19746	Nov 12, 1992	wo						
	WO 93/15722	Aug 19, 1993	wo						
V	WO 94/26285	Nov 24, 1994	wo	T					

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
On	A17	Basch, Ross S. (1990) Aging: Immunology and Infectious Disease, Vol. 2, No. 4, 229-235
1	A18	Batard et al., (2000) J. Cell. Sci. 113:383-90
	A19	Bauer, G., et al., (1997) Blood 89:2259-2267
	A20	Belmont and Jurecic (1997) "Methods for Efficient Retrovirus-Mediated Gene Transfer to Mouse Hematopoietic Stem Cells," in <u>Gene Therapy Protocols</u> (P.D. Robbins, ed.), Humana Press, pp. 223-240
V	A21	Berzins et al., (1999) Proc. Natl. Acad. Sci. USA (17): 9787-9791

EXAMINER	1	DATE CONSIDERED	67
V and 1		7/10	<i> </i>

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

4

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003

Group Art Unit 1645 763.2

		U.S.	Patent Documen	ts			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
0.4	5,061,620	Oct 29, 1991	Tsukamoto et ál.	•			
	5,073,624	Dec 17, 1991	Coy et al.				
	5,144,019	Sep 1, 1992	Rossi et al.			-	
	5,199,942	Apr 6, 1993	Gillis		1		
	5,258,492	Nov 2, 1993	Schally et al.				
	5,736,524	Apr. 7, 1998	Content et al.				
	5,399,493	Mar 21, 1995	Emerson et al.	· · · · · · · · · · · · · · · · · · ·			
	5,410,016	Apr 25, 1995	Hubbell et al.				
	5,506,207	Apr 9, 1996	Rivier et al.				

Foreign Patent Documents							
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER	DATE	COUNTRY		SUBCLASS	YES	NO
0.7	WO 94/26877	7 Nov 24, 1994	wo				
1	WO 95/08105	Mar 23, 1995	WO				
	WO 96/14853	Mar 23, 1996	· wo				
	WO 96/33281	Oct 24, 1996	WO				
V	WO 96/33282	Oct 24, 1996	wo				

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
חה	A22	Berzins, S.P., Boyd, R.L. and Miller, J.F.A.P., (1998) <i>J Exp. Med.</i> 187: 1839
7	A23	Bloom and Murray, (1993) Science 257, 1055
	A24	Bodey et al., (1997) In Vivo 11(4): 351-370
	A25	Bodey et al., (1997) In Vivo 11(5): 421-440
	A26	Bolotin et al., (1996) Blood 88:1887
	A27	Bolotin et al., (1999) Bone Marrow Transplant, 23(8): 783-788
U	A28	Bonato et al., (1998) Infection and Immunity, 66(1): 169-175

EXAMINER DATE CONSID	,
	RED
(al 1 8/19)	97

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

5

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

		U.S. I	Patent Docume	nts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DA	5,559,703	Sep 24, 1996	lwata et al.		1	
	5,614,187	Mar 25, 1997	Sachs			
	5,614,502	Mar 25, 1997	Flotte et al.			
	5,624,823	Apr 29, 1997	Sachs et al.			
	5,643,252	Jul 1, 1997	Waner et al.			
,	5,658,564	Aug 19, 1997	Sykes et al.			
V	5,658,822	Aug 19, 1997	Wu et al.			

Foreign Patent Documents								
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
INITIAL	NUMBER	DATE	000111111	CLAGO		YES	NO	
\mathcal{D}_{a}	WO 98/08533	Mar 5, 1998	WO					
	WO 98/23325	Jun 4, 1998	WO					
	WO 99/29728	Jun 17, 1999	WO					
	WO 99/32619	Jul 1, 1999	. WO					
V	WO 99/53050	Oct 21, 1999	wo					

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
QM	A29	Bonyhadi, M.L., <i>et al.</i> , (1997) <i>J. Virology</i> 71:4707-4716
	A30	Borremans et al., (1989) Infect. Immunity 57:3123
	A31	Boyd, R.L., Tucek, C.L., Godfrey, D.I., Wilson, T.J, Davidson, N.J., Bean, A.G.D., Ladyman, H.M., Ritter, M.A. and Hugo, P., (1993) <i>Immunology Today</i> 14:445
·	A32	Bruijntjes, J.P., Kuper, C.J., Robinson, J.E. and Schutirman, H.J., (1993) <i>Dev. Immunol.</i> 3:113
	A33	Capecchi, M.R., (1980) <i>Cell</i> 22:479-488
	A34	Carayon, P., and Bord, A., (1992) <i>J. Imm. Methods</i> 147:225

EXAMINER /	DATE CONSIDERED
1/2 A	a 8/10/07
L Care /	<u> </u>
EXAMINER: Initial if citation is considered	whether or not citation is in conformance with MPER &

609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

6

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date
December 30, 2003

Group Art Unit 1645 1632

U.S. Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	TO THE TOTAL		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
017	5,658,892	Aug 19, 1997	Flotte et al.				
1	5,681,559	Oct 28, 1997	DiGiusto et al.				
	5,736,524	Apr 7, 1998	Content et al.				
	5,741,706	Apr 21, 1998	Leavitt et al.				
	5,811,275	Sep 22, 1998	Wong-Staal et al.				
	5,814,617	Sep 29, 1998	Hoffman et al.				
	5,839,446	Nov 24, 1998	Waner et al.				

Foreign Patent Documents								
EXAMINER	DOCUMENT	DATE	COUNTRY	COUNTRY CLASS SUBSI	SUBCLASS	TRANSLATION		
INITIAL	NUMBER	DATE	COUNTRY	CLASS	SUBCEASS	YES	NO	
01	WO 01/34815	May 17, 2001	wo					
DM	WO 03/51272	Jun 26, 2003	WO					

			Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
a	4	A35	Castle, S.C., (2000) Clin Infect Dis 31(2): 578-585
		A36	Charoenvit et al., (1991) J. Immunol. 146: 1020
		A37	Coleman et al., (1989) Ultrasound Med. Biol. 15:213-227
		A38	Consolini et al., (2000) Clin. Exp. Immunol. 121(3): 444-447
		A39	Davis et al. (1998) Hum. Gene Ther., p. 1197-207
		A40	Dawe et al., (1993) Springer Semin. Immunopathol. 14:285
J		A41	Denis et al., (1998) Infection and Immunity, (66)4:1527-1533

XAMINER	1	DATE CONSIDERED

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

1645 1652

		U.S.	Patent Documer	nts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
nΛı	5,876,708 Mar 2, 1999 Sachs		Sachs			
VI	6,030,833	Feb 29, 2000	Seebach et al.			
	6,056,738	May 2, 2000	Marchitto et al.			
	6,251,099	Jun 26, 2001	Kollias et al.			
	6,296,846	Oct 2, 2001	Sachs et al.			
	6,306,651	Mar 23, 2001	Sachs			
	6,315,772	Nov 13,2001	Marchitto et al.			
\overline{V}	6,492,145	Dec 10, 2002	Lowrie			

Foreign Patent Documents							
EXAMINER INITIAL	DATE COUNTRY CLASS SUBCLASS						
	7701110211					123	140

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
$\rho \wedge$	A42	DeWit et al., (1994) DNA Seq. 4:267
	A43	DiGusto et al., (1997) Blood 87:1261
	A44	Doria, G., Mancini, C., Utsuyama, M., Frasca, D. and Hirokawa, K, (1997) <i>Mech. Age. Dev.</i> 95: 131-142
	A45	Douek et al., (2000) Lancet 355:1875
	A46	Douek et al., (2001) J. Immunol. 167:6663-8
	A47	Douek, D.C., McFarland, R.D., Keiser, P.H., Gage, E.A., Massey, J.M., Haynes, B.F., Polis, M.A., Haase, A.T., Feinberg, M.B., Sullivan, J.L., Jamieson, B.D., Zack, J.A., Picker, L.J. and Koup, R.A., (1998) <i>Nature</i> 396:690
	A48	Dougherty and Parks, (1995) Curr. Opin. Cell Biol. 7:399
	A49	Doukas et al., (1995) Ultrasound Med. Biol. 21:961
,	A50	Dreger et al., (1993) Blood 81:1404
	A51	Ellis et al., (2001) Int. Immunol. 13:553-558

			<u> </u>
EXAMINER /		DATE CONSIDERED	
		///-	
. (/		0/1/5/	•
1 ou		6/10/07	
CVANILLED	/		

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

8

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003

Group Art Unit 1645 /632

U.S. Patent Documents							
EXAMINER INITIAL	DATE I NAME I CLASS I SUBCLASS I TELLO						
DA	6,558,663	May 6, 2003	Seebach et al.				

Foreign Patent Documents							
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER	DATE	COONTAI	02700	SUBCLASS	YES	NO
			,		· ·		
	•				1		

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
07	A52	Engel et al., (1999) Frontiers in Bioscience 4, e26-33
	A53	Erben et al., (2001) Horm. Metab. Res. (2001) 33:491
	A55	Ernst et al., (1990) J. Immunol. 145:1295
	A55	Fabris et al., (1997) Cell Mol. Biol., 43(4): 529-541
		Fabris and Mocchegiani, (1995) Aging Apr; 7(2): 77-93
	A56	Fabro et al., (1990) J. Appl. Phys. 68:775,
	A57	Faith et al., (1991) Immunol. 74:1
	A58	Faltynek et al., (1992) J. Immunol. 149:1276
	A59	Fan et al., (2002) J. Immunol. 168:755-62
	A60	Fearon and Locksley (1996) Science 272:50
	A61 -	Fernando et al., (1999) Clin. Exp. Immunol. 115:397
	A62	Fitzpatrick et al., (1987) J. Endocr. 113, 51-55
	A63	Flurkey et al., (1992) J. Gerontol. 47:B115
	A64	Flynn et al., (1992) Proc. Natl. Acad. Sci. USA 89:12013
	A65	Franke et al., (2000) Infect. Immun. 68:3403
	A66	Fredrickson, G.G. and Basch, R.S., (1994) Development and Comparative Immunology 18:251
	A67	Fry et al., (2001) Blood 97(6): 1525-1533
	A68	Fry, et al., (2001) Trends Immunol. 22(10): 564-571
	A69	Garrovillo et al., (1999) Transplantation 68:1827
	A70	Garrovillo et al., (2001) Am. J. Transplant. 1:129

EXAMINER Jank	DATE CONSIDERED
EXAMINEA: Initial if citation is considered, wheth 609: Draw Line through citation if not conformance	er or not citation is in conformance with MPEP § and not considered. Include copy with next

communication to applicant.

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number NOR-014CP4/ 286336.153US1 **Application Number** 10/749,122

Applicant Boyd, Richard

Filing Date

Group Art Unit

9 OF December 30, 2003 1645/632 Sheet 17

tha	A71	Garzetti et al., (1996) Obstet. Gynecol. 88: 234-40
1	A72	George, A. J. and Ritter, M.A., (1996) Immunol. Today 17:267
	A73	Gill et al., (2002) Nat. Immunol. 3:635
	A74	Girasole et al., (1992) J. Clin. Invest. 89:883
A75		Godfrey, D. I, and Zlotnik, A., (1993) Immunol. Today 14:547
	A76	Godfrey, D.I, Izon, D.J., Tucek, C.L., Wilson, T.J. and Boyd, R.L., (1990) Immunol. 70:66
		Goldberg et al., (2003) Poster Presentation, ASBMT, Keystone USA
	A77	Goldberg et al., (2003) Abstract, ASBMT, Keystone USA
	A78	Goldberg et al., (2002) Abstract/Poster Presentation ASH, Philadelphia USA
	A79	Goldberg et al., (2002) Abstract of Oral Presentation, Immunology Group of Victoria, Beachworth AU
	A80	Graham, F.L. and Van Der Eb, A.J., (1973) <i>Virology</i> 52:456-457
	A81	Greenstein et al., (1987) J. Endocr., 112, 345-350
	A82	Greenstein et al., (1986) J. Endocr. 110, 417-422
	A83.	Grossman, Charles J. (1984) Endocrine Reviews, 5(3): 435-455
	A84	Grossman, Charles J. (1985) Science 227: 256-261
	A85	Hadden, John W. (1998) New York Academy of Sciences, 840: 352-358
	A86	Hannet et al., (1992) Immunol. Today, June; 13(6): 215-218
	A87	Haseloff and Gerlach (1988) Nature 334:585
	A88	Haynes, B.F., Hale, L.P., Weinhold, K.J., Patel, D.D., Liao, HX., Bressler, P.B., Jones D.M., Demarest, J.F., Gebhard-Mitchell, K., Haase, A.T. and Bartlett, J.A., (1999) <i>J. Clin. Invest.</i> 103: 453-460
/	A89	Hazenberg et al., (2001) J. Mol. Med. 79:631-40
1	A90	Heitger, A., Neu, N., Kern, H. and Fink, F.M., (1997) Blood 90: 850-857

EXAMINER //	DATE CONSIDERED/
Var to	8/1907
EXAMINER: Initial if citation is considered, wheth	er or not citation is in conformance with MPEP §
609: Draw Line through citation if not conformance	and not considered. Include copy with next
communication to applicant.	

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

10

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit 1645/632

Or,	}	A91	Heitger, A., Winklehner, P., et al., (2002) <i>Blood</i> 99:4053-4062
		A92	Hertogh-Huijbregts et al., (1990) Mech. Ageing Dev. 53:141-155
		A93	Hirokawa, K. and Makinodan, T., (1975) J. Immunol. 114:1659
		A94	Hirokawa, (1998) "Immunity and Ageing," in PRINCIPLES AND PRACTICE OF GERIATRIC MEDICINE, (M. Pathy, ed.) John Wiley and Sons Ltd.
		A95	Hirokawa, K., Utsuyama M., Kasai, M., Kurashima, C., Ishijima, S. and Zeng, YX., (1994) <i>Immunology Letters</i> 40:269
		A96	Hobbs, M.V., Weigle, W.O., Noonan, D.J., Torbett, B.E., McEvilly, R.J., Koch, R.J., Cardenas, G.J. and Ernst, D.N., (1993) <i>J. Immunol.</i> 150:3602
		A97	Hochberg et al., (2001) Blood 98:1116-21
		A98	Hoffman et al., (1991) Science 252: 520
		A99	Homo-Delarche et al., (1993) Springer Sem. Immunopathol. 14:221
		A101	Hsu et al., (2000) Cancer Res. 60:3701
		A102	Hu et al., (1993) Int. Immunol. 5:1035-1039
		A103	Huiskamp, R., Davids, J.A.G. and Vos, O., (1983) Radiation Research 95:370
		A104	Huiskamp <i>et al.</i> , (1985) <i>J. Immunol.</i> , 134(4): 2161-2171
		A105	Huygen et al., (1992) Infect. Immunity 60:2880
		A106	Igarashi et al., (2001) Proc. Natl. Acad. Sci. USA, 98(26): 15131-15136
	T	A107	Jacobson et al. (1999) Endocrinology, 140(8): 3429-3437
		A108	Jacobson et al., (1999) J. Allergy Clin. Immunol., 104(3): Pt. 1, 653-658
	,	A109	Jacobson et al., (1994) Endocrinology, Vol. 184(6): 2516-2523
,	IJ	A110	Janeway et al., (2001) Immunobiology 5th Ed., p. 325

EXAMINER	1th	S/1407
		· · · · · · · · · · · · · · · · · · ·

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

11

OF

17

Docket Number NOR-014CP4/ 286336.153US1 **Application Number** 10/749,122

Applicant Boyd, Richard

Filing Date

Group Art Unit

December 30, 2003

pA	A11	Jansson et al., (1994) J. Neuroimmunology 53:203-207
- 1	A11	Jenkinson et al., (1985) Transplantat. 39:331
	A11	Junker et al., (1998) <i>Hum Gene Ther.</i> , p. 333-40
	A11	Kamradt, T. and Mitchison, N.A., (2001) N. Engl. J. Med. 344:655-664.
	A11	Kendall et al., (1990) Cell Tissue Research, 261(3)555-64
	A11	Kendall, (1988) "Anatomical and physiological factors influencing the thymic microenvironment," in THYMUS UPDATE I, Vol. 1. (M. D. Kendall, and M. A. Ritter, eds.) Harwood Academic Publishers, p. 27
	A11	Kincade et al., (2002) Immunology, 14: 385-394
	A11	Kincade et al. (2000) Immunological Reviews, 175: 128-137
	A11	Kirschmann et al., (1992) Cell. Immunol. 139:426
	A12	Kissin <i>et al.</i> , (1987) <i>Radiology</i> , 163(1): 67-70
	A12	Kohen et al., (1998) Developmental Immunology, 5: 277-285
·	A12	Kohn, D.B., et al., (1999) Blood 94:368-371
	A12	Komschlies et al., (1995) J. Leukoc. Biol. Dec.; 58(6): 623-633
	A12	Kouro et al., (2001) Blood 97:2708
	A12	Krijanovski, <i>et al.</i> , (1999) <i>Blood</i> 94:825
	A12	7 Krug (2004) Sem. Oncol. 31:112
	A12	Kurashima, C, Utsuyama, M., Kasai, M., Ishijima, S.A., Konno, A. and Hirokawa, A., (1995) Int. Immunol. 7:97
	A12	Landstrom et al., (1997) Int. J. Cancer 71, 451-455
	A13	LeMaoult <i>et al.</i> , (1999) <i>J. Immunol</i> . 162:6384-6391
	/ A13	LeMaoult et al., (2000) J. Immunol. 165:2367
t	A13	Longovio et al. (1995) Neuroimmunadulation 2:100-107

\sim		
EXAMINER / aul &	DATE CONSIDERED	

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

12

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

Lewin et al., (2002) Blood 100:2235 A134 Lin et al., (1996) Cancer Res. 56:21 A135 Lincz et al., (2001) Leuk. and Lymph. 40: 373 A136 Mackall et al., (1997) Immunology Today, 18(5): 245-251 A138 A139 Mackall, C.L. and Gress, R.E., (1997) Immunol. Rev. 160:91 Mackall, C.L. et al., (1995) New England J. Med. 332:143 A140 Mackall, C.L., Punt, J.A., Morgan, P., Farr, A.G. and Gress, R.E., (1998) Eur. J. A141 Immunol. 28: 1886-1893 A142 Maraskovsky et al., (1997) Cell 89(7): 1011-9 A143 Martinez et al., (2003) J. Clin Invest. 111:1365 A144 Masuzawa et al., (1994) J. Clin. Invest. 94:1090 A145 Matera L, Neuroimmunomodulation (1997) 4(4): 171-80 Matzinger et al., (1989) Nature 338:74-60 A146 Medina et al., (2001) Nat. Immunol. 2:718 A147 Mercader et al., (2001) PNAS 98(25): 14565-14570 A148 Miller et al., (1976) J. Immunol. 117:1519 A149 A150 Mocchegiani et al., (1990) Horm. Res. 33(6): 248-55 Morale et al., (1991) Endocrinology, 128(2): 1073-1085 A152 Morelli et al., (2001) Semin. Immunol. 13:323-335 A153 Morrissey et al., (1991) J. Immunol. 146:1547 A154 Mosley et al., (1998) Cell. Immunol. 189:10 A155 A156 Murasko, D.M., Bernstein, E.D., et al., (2002) Exp. Gerontol. 37:427-439 Nabel, E.G. et al., (1992) Hum. Gene Ther. 3:649-656 A157

EXAMINER /	DATE CONSIDERED	
	/ /	
	G/10/2	
1/8/	8/10/0 t	
EVALUATED		

Nicoletti et al., (1993) J. Immunol. 150:543-549

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

A158

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

13

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

A159 Nikolic et al., (2000) Blood, 96(3): 1166-1172 A160 Noach et al., (2002) Blood 100:312 A161 Nowak, Rachel (1999) New Scientist, pg. 11 A162 Oberbeck R., (2003) J. Surg Res. 113(2): 248-56 A163 Ohnishi et al., (2003) Int. J. Mol. Med. 1:331 A164 Oliver et al., (1995) Urol. Int., 54:226-229 A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panerai et al., (1997) Immunol. Rev. 157:73 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci., U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930 V A183 Podda et al., (1992) Proc. Natl. Acad. Sci. USA 89:9676			
A161 Nowak, Rachel (1999) New Scientist, pg. 11 A162 Oberbeck R., (2003) J. Surg Res. 113(2): 248-56 A163 Ohnishi et al., (2003) Int. J. Mol. Med. 1:331 A164 Oliver et al., (1995) Urol. Int., 54:226-229 A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Perit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930	DM	A159	Nikolic et al., (2000) Blood, 96(3): 1166-1172
A162 Oberbeck R., (2003) J. Surg Res. 113(2): 248-56 A163 Ohnishi et al., (2003) Int. J. Mol. Med. 1:331 A164 Oliver et al., (1995) Urol. Int., 54:226-229 A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A160	Noach et al., (2002) Blood 100:312
A163 Ohnishi et al., (2003) Int. J. Mol. Med. 1:331 A164 Oliver et al., (1995) Urol. Int., 54:226-229 A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A161	Nowak, Rachel (1999) New Scientist, pg. 11
A164 Oliver et al., (1995) Urol. Int., 54:226-229 A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Perit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A162	Oberbeck R., (2003) J. Surg Res. 113(2): 248-56
A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A163	Ohnishi et al., (2003) Int. J. Mol. Med. 1:331
A165 Olsen et al., (2001) Endocrinol. 142:1278 A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930	- 	A164	Oliver et al., (1995) Urol. Int., 54:226-229
A166 Olsen, et al., (2001) J. Clin. Invest. 108:697 A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortma et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930			Olsen et al., (2001) Endocrinol. 142:1278
A167 Oluwole et al., (1993) Transplantation 56:1523-1527 A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24			
A168 Oosterwegel et al., (1997) Immunity 6(3): 351-360 A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24			
A169 Orme et al., (1993) J. Infect. Dis. 167:1481 A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930			
A170 Ortman et al., (2002) Int. Immunol. 14:813 A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930	- 1		
A171 Pacheco et al., (1979) J. Parisitol. 65:414 A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 J/ A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930			
A172 Panerai and Sacerdote, (1997) Immunol. Today 4: 191-192 A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930			
A173 Panoskaltsis, N, and C.N. Abboud, (1999) Frontiers in Bioscience 4:457 A174 Panoskaltsis-Mortari et al., (2000) Blood 96:4350 A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A172	· · · · · · · · · · · · · · · · · · ·
A175 Parkman et al., (1997) Immunol. Rev. 157:73 A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Playec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A173	
A176 Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269 A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Playec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A174	Panoskaltsis-Mortari et al., (2000) Blood 96:4350
A177 Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547 A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Playec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A175	Parkman et al., (1997) Immunol. Rev. 157:73
A178 Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25 A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Playec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A176	Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269
A179 Perriman et al., (1992) Gene 113:157 A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Playec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A177	Penit, C. and Ezine, S., (1989) Proc. Natl. Acad. Sci, U.S.A. 86:5547
A180 Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960 A181 Plavec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A178	Penit, C., Lucas, B., Vasseur, F., Rieker, T. and Boyd, R.L., (1996) Dev. Immunol. 5:25
A181 Plavec et al., (1996) Gene Ther, p. 717-24 // A182 Plosker, G.L. and Brogden, R.N., (1994) Drugs 48:930		A179	Perriman et al., (1992) Gene 113:157
// A182 Plosker, G.L. and Brogden, R.N., (1994) <i>Drugs</i> 48:930		A180	Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960
		A181	Plavec et al., (1996) Gene Ther, p. 717-24
V A183 Podda et al., (1992) Proc. Natl. Acad. Sci. USA 89:9676		/ A182	Plosker, G.L. and Brogden, R.N., (1994) <i>Drugs</i> 48:930
	- 1 /	Δ183	Podda et al., (1992) Proc. Natl. Acad. Sci. USA 89:9676

EXAMINER / /	DATE CONSIDERED
	7/-
// 🔼	T/11/12
Vaul V	1/19/1
EVANALED	

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

14

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

61	A184	Potter, H., Weir, L., and Leder, P., (1984) Proc. Natl. Acad. Sci. USA 81:7161-7165
Ī	A185	Prasad et al., (1988) J. Clin. Invest. Oct; 82(4): 1202-1210
7	A186	Randle-Barrett and Boyd (1995) Dev. Immunol. 4:101
1	A188	Ranga et al., (1998) Proc. Natl. Acad. Sci. USA 95:1201
	A189	Rao et al., (1994) Am. J. Reproductive Immunology, 32:238-247
	A190	Renia et al., (1993) J Immunol. 150:1471
	A191	Repique et al., (2002) Infection and Immunity, p. 3318-3323
	A192	Robinson, et al. (2000) Adv. Virus Res. 55:1-74
	A193	Rodrigues et al., (1991) Int. Immunol. 3: 579
	A194	Romain et al., (1993) Proc. Natl. Acad. Sci. USA 90:5322
	A195	Rosenzweig et al., (1997) Blood, 90(12): 4822-4831
	A196	Rossi, S., Blazar, B.R., et al., (2002) Blood 100:682-691
	A197	Sato et al., (2004) Br. J. Cancer 90:1334
	A198	Scollay, R.G., Butcher, E.C. and Weissman, I.L., (1980) Eur. J. Immunol. 10:210
	A199	Seder and Paul (1994) Annu. Rev. Immunol. 12:635
	A200	Segeren et al., (1999) Br. J. Haem. 105: 127-130
	A201	Sempowski et al., (2002) Mol. Immunol. 38:841-84
	A202	Sempowski, G.D., Hale, L.P., Sundy, J.S., Massey, J.M., Koup, R.A., Douek, D.C., Patel, D.D. and Haynes, B.F., (2000) <i>J. Immunology</i> 164: 2180-2187
	A203	Shaffer and Scher (2003) Lancet Oncol. 4:407
	A204	Shippy et al., (1999) Mol. Biotechnol.12: 117
	A205	Shortman, K., Egerton, M., Spangrude, G.J. and Scollay, R., (1990) Seminars in Immuno. 2:3
	/ A206	Shu et al., (1993) J. Virol. 67:2723
	A208	Shull et al., (1992) Nature 359:693

EXAMINER //	DATE CONSIDERED
	1 / / / /
(Out /V)	9190

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

15

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

<i>f</i>)/\	A209	Silva and Lowrie, (1994) Immunol. 82:244
T	A210	Smithson et al., (1995) J. Immunol. 155:3409
$\neg \uparrow$	A212	Smithson et al., (1998) J. Immunol. 161:27-35
	A213	Soares et al., J. Immunol. (1998) 161:5909-5917
	A214	Starzl, T.E., Demetris, A.J., Murase, N., Ricardi, C. and Truce, M., (1992) Lancet 339:1579
	A215	Steffens et al., (2000) Clin. Immunol. 97:95
	A216	Stern et al., (1989) Corneal Laser Ablation, 107: 587-592
	A217	Storek et al., (1997) Am. J. Hematol. 54:131
	A218	Storek et al., (2001) Blood 98:3505
	A219	Strayer, D.S., Branco, F. et al., (2002) Therapy 5:33-41
	A220	Suda and Zlotnik, (1992) J. Immunol. 149(1): 71-76
	A221	Suda, T., and Zlotnik, A., (1991) J. Immunol. 146:3068
	A222	Takeoka, Y., Taguchi, N. et al., (1999) Clin. Immunol. 90:388-398
	A223	Talwar, (1999) <i>Immunol. Rev.</i> 171:173-92
	A224	Tang et al., (1997) J. Immunol. 159:117
	A225	Tanghe, et al., (2001) Infection and Immunity, p. 3041-3047
	A226	Tanghe et al., (2000) Infection and Immunity 68(7): 3854-3860
	A227	THE JORDAN REPORT 2000: ACCELERATED DEVELOPMENT OF VACCINES, published by the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (available at http://www.niaid.nih.gov/publications/pdf/jordan.pdf —last visited Apr. 2004)
	A228	Thomas-Vaslin, V., Damotte, D. et al., (1997) P.N.A.S. (U.S.A.) 94:4598-4603
1/	A229	Thomson, A.W. and Lu, L., (1999) Immunology Today 20(1):27
- 1	A230	Thurmond et al., (2000) Endocrinol. 141:2309

EXAMINER Paul A	DATE CONSIDERED	
EVAMINED: Initial if citation is considered who	ther ar not citation is in conformance with MPER 6	_

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

16

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

b^{Λ}	(A231	Timm, J.A. and Thoman, M.L., (1999) J. Immunol. 162:711
	·	A232	Tomita et al., (1994) J. Immunol. 153:1087-1098
		A233	Tosi et al., (1982) Clin. Exp. Immunol. Feb; 47(2): 497-504
		A235	Ulmer et al., (1993) Science 259:1745
		A236	Umesaki et al., (1999) Gynecol. Obstet. Invest. 48:66-8
		A237	Utsuyama et al, (1989) Mech. of Ageing Dev. 175-185
		A238	Utsuyama et al., (1995) Mech. Ageing Dev. 107-117
		A239	van Ewijk <i>et al.</i> , (1991) <i>Annu. Rev. Immunol.</i> 9:591-615
		A240	van Ewijk, W., Rouse, R.V. and Weissman, I.L., 1980 J. Histochem. Oct 28(10): 1089
		A241	Viselli et al., (1997) Cellular Immunology 182, 99-104
		A242	Viselli et al. (1995) Immunology 84: 337-342
		A243	Vickery et al., (1984) LHRH AND ITS ANALOGS: CONTRACEPTIVE & THERAPEUTIC APPLICATIONS (Vickery et al., eds.) MTP Press Ltd., Lancaster, PA
		A244	Von Freeden-Jeffry, U., Vieira, P., Lucian, L.A., McNeil, T., Burdach, E.G. and Murray, R., (1995) J. Exp. Med. 181:151
		A245	Waldrop et al., (1998) J. Immunol. 161(10): 5284-95
	•	A246	Wang et al., (2003) Br. J. Cancer 88:887
		A247	Waterhouse et al., (1998) Proc. Natl. Acad. Sci. USA 95:13959
		A248	Weinberg et al., (1995) Biol. Blood Marrow Transplant1 (1): 18-23
		A249	Weiss et al., (1988) Proc. Natl. Acad. Sci USA 85:573
		A250	Weiss et al., (1992) J. Immunol. 149:2103
		A251	Weksler et al., (2000) Vaccine 18:1624-1628
		A252	Weyand, C.M., Brandes, J.C., Schmidt, D., Fulbright, J.W. and Goronzy, J.J., (1998) Mech. Age. Dev. 102: 131-147

EXAMINER		- 11	DATE CONSIDERED	
			8/10/67	
	1/1/4		. 0/170/	

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

17

OF

17

Docket Number NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit

D/	4	A253	Wiker and Harboe, (1992) Microbiol. Rev. 56: 648
	1	A254	Wiles, M.V., Ruiz, P. and Imhof, B.A., (1992) Eur. J. Immunol. 22:1037
		A255	Wilson et al., (1995) Blood 85:1535
		A256	Windmill and Lee, (1998) Tissue Cell 30(1): 104-111
		A257	Windmill et al. (1993) Reprod. Fertil. Devl. 5, 73-81
		A258	Woffendin et al., (1994) Proc. Natl. Acad. Sci. USA, 91:11581
		A259	Woffendin et al., (1996) Proc. Natl. Acad. Sci. USA, 93:2889
		Å260	Wu et al., (1996) Am. J. Repro. Immunol. 35(6): 510-516
		A261	Yang, NS. and P. Ziegelhoffer, (1994) "The Particle Bombardment System for Mammalian Gene Transfer," In PARTICLE BOMBARDMENT TECHNOLOGY FOR GENE TRANSFER (Yang, NS. and Christou, P., eds.), Oxford University Press, New York, pp. 117-141
		A262	Young and Garbe, (1991) Res. Microbiol. 142:55
	/	A263	Zhang et al., (1999) J. Exp. Med. 190:725
		A264	Zlotnik, A. and Moore, T.A., (1995) Curr. Opin. Immunol. 7:206.

EXAMINER ()	DATE CONSIDERED
() (1	Chiston .
L/acl/D	811967

MON O 2 200

bt. For, PTO-1449

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

OF

1

Docket Numbers NOR-014CP4/ 286336.153US1 Application Number 10/749,122

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit 1645/632

		U.S.	Patent Docume	nts		٠ .
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Dŗ	10/399,213	N/A	Boyd	N/A	N/A	Apr 14, 2003
	10/748,450	N/A	Boyd	N/A	N/A	Dec 30, 2003
	10/749,118	N/A	Boyd	N/A	N/A	Dec 30, 2003
	10/749,119	N/A	Boyd	N/A	N/A	Dec 30, 2003
	10/749,120	N/A	Boyd et al.	N/A	N/A	Dec 30, 2003
	10/748,831	· N/A	Boyd	N/A	N/A	Dec 30, 2003

		Foreign	Patent Docum	ents			
EXAMINER	DOCUMENT	DATE	DATE COUNTRY CLAS	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER	DATE		OBAGO	00000000	YES	NO
//\	WO 00/62657	Oct 26, 2000	PCT		.]		
//							
				,			
				 			
					1 1		

 Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

EXAMINER	1/2 1/2	DATE CONSIDERED	
	1.01	0/0/0-	

	PRMATION		Docket Numbers Application Number NOR-014CP4 and 286336.153US1		
" 3 0 1005 m	IN AN APP		· •	Applica Boyo	•
M M				Filing Date	Group Art Unit
TRAD TO Sheet	1	OF	1	December 30, 2003	1632

		U.S	S. Patent Documer	nts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M	6,103,694	Aug 15, 2000	Mardiney, III et al.	514	12	Apr 10, 1998
	,					

		For	eign Patent Docume	ents			
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	LATION
INITIAL	NUMBER					YES	NO

			Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
n.	1	A265	Ghalie et al., "Prevention of Hypermenorrhea With Leuprolide in Premenopausal Women Undergoing Bone Marrow Transplantation," American Journal of Hematology, 1993, Vol. 42, pp 350-353
	'	A266	Kojima et al., "Immunosuppressive Therapy Using Antithymocyte Globulin, Cyclosporine, and Danazol With or Without Human Granulocyte Colony-Stimulating Factor in Children With Acquired Aplastic Anemia," Blood, September 15, 2000, Vol. 96, No. 6, pp 2049-2054
		A267	Masera et al., "Is Orchiectomy Indicated Before BMT in Childhood ALL?" Bone Marrow Transplant, 1991, Vol. 8, No. S1, pp 33-35
	1	A268	Vogelsang et al., "Thalldomide Induction of Bone Marrow Transplantation Tolerance," Transplantation Proceedings, 1987, Vol. XIX, No. 1, pp 2658-2661
	_		

EXAMINER OUT	DATE CONSIDERED.
EXAMINER: Initial if citation is considered, whether or not citaticitation if not conformance and not considered. Include copy with	

Subt. For, PTO-1449			Docket Number	Application Number
OTP E INFORMAT	ION DISCLO		NOR-014CP4 ⁷ 286336.153	10/749,122
Auf 1 5 Music Structure Severa	I sheets if nece	essary)	Applica Boye	
TATA TRANSPORT			Filing Date	Group Art Unit
Sheet 1	OF	1	December 30, 2003	1645/632

	-	U.S. Pate	ent Documents	
Examiner Initial	Document Number	Publn. Date mm-dd-yyyy	Name Of Patentee Or Applicant Of Cited Documents	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
0/1	US-5,760,000	06/02/1998	Habibi	
DA	US-2005/0043245	02/24/2005	Siler-Khodr	
				1
				. (

		Foi	eign Patent D	ocuments	
Examiner Initial	Cite No.	Foreign Patent Document Country Code-Number- Kind	Publn. Date mm-dd-yyyy	Country	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
PM		WO 01/74377	10/11/2001	PCT	
bA		WO 02/31110	04/18/2002	PCT	

Examiner's Initial	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)					tc.)	
			· 		,		
			,		•		•
			•				

EXAMINER ///	DATE CONSIDERED // / ¬
Kur	K160/2+
EXAMINER: Initial if citation is considered, whether or not citati	on is in conformance with MPEP § 609: Draw Line through
citation if not conformance and not considered. Include convivity	

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	stitute for form 1449A/B/P	TO	-	Complete if Known		
		. •		Application Number	10/749122-Conf. #3280	
11	NFORMATIO	N DI	SCLOSURE	Filing Date	December 30, 2003	
l s	TATEMENT	BY A	APPLICANT	First Named Inventor	Richard L. BOYD	
_				Art Unit	1644 1632	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned Montains 6A	
Sheet	1	of	1	Attorney Docket Number	286336.153US1/NOR-014CP4	

	U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where			
Initials*		Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
DA	AA*	US-5,434,136	07-18-1995	Mathias				
	AB*	US-5,985,892	11-16-1999	Walsh et al.	·			
	AC*	US-5,760,000	06-02-1998	Habibi				
V	AD*	US-2005/0043245	02-24-2005	Siler-Khodr				

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
UM	ВА	WO-01/74377	10-11-2001	Siler-Khodr and Khodr		\Box		
DN	BB	WO-02/31110	04-18-2002	Boyd				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	One	16	Date Considered	8/10/07
5 40 7 4 0 4	 			

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

OIPE 40 2006 W

Sheet

PTO/SB/08a/o (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 0 1

Complete if Known					
Application Number	10/749122-Conf. #3280				
Filing Date	December 30, 2003				
First Named Inventor	Richard L. BOYD				
Art Unit	1845 1632				
Examiner Name .	Not Yet Assigned Mostanni BA				
Attorney Docket Number	0286336.00153US1/NOR-014CP4				

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Floures Appear			
					•			

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	٦٥			
				·					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Not indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

•	-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
DM	CA	FITZPATRICK et al., "Reappearance of Thymus of Ageing Rats after Orchidectomy," Journal of Endocrinology, 1985, pp. R17-R19, Vol. 106.	
0/1		OLSEN et al., "Androgen Deprivation Induces Phenotypic and Functional Changes in the Thymus of Adult Male Mice," Endocrinology, 1991, pp. 2471-2476, Vol. 129, No. 5.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	1 had	M	Date Considered	8/10/07
		, —		

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

APR 2 7 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

•					
Complete if Known					
10/749122-Conf. #3280					
December 30, 2003					
Richard L. BOYD					
1645 /632					
Not Yet Assigned Murtani, A					
286336.153 US1/NOR-014CP4					

U.S. PATENT DOCUMENTS							
Examiner Cite		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
DPT	AA*	US-6,248,329	06-19-2001	Chandrashekar et al.			

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,			
initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Petent Documents at www.uspio.gog or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
DA	CA	Ellis, "New Technologies for Making Vaccines," Chapter 29 of "Vaccines", Plotkin et al., 1998, pp. 568-574.				
	СВ	Ezzell NIH Research, "Cancer 'Vaccines': An Idea Whose Time Has Come?" 1995, Vol. 7, pp. 46-49.				
	CC	Feldman et al., "Anti-TNF∝ Therapy is Useful in Rheumatoid Arthritis and Crohn's Disease: Analysis of the Mechanism of Action Predicts Utility in Other Diseases," Transplantation Proceeding, 1998, Vol. 30, pp. 4126-4127.				
V	CD	Spitler, "Cancer Vaccines: The Interferon Analogy," Cancer Biotherapy, 1995, Vol. 10, pp. 1-3.				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	Dar Mo	Date Considered	8/10/7
	-		7 /

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it.

Sut	stitute for form 1449A/I	в/РТО		Complete if Known		
l .	•			Application Number	10/749122-Conf. #3280	
11	NFORMATIO	ON DISC	LOSURE	Filing Date	December 30, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Richard L. BOYD	
				Art Unit	1645 /622	
	(Use as many sheets as necessary)			Examiner Name -	Not Yet Assigned Marthus 1124	
Sheet	1	of	1	Attomey Docket Number	0286336.00153US1/NOR-014CP4	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Occument	Publication	Name of Patentee or	Pages, Columns, Lines,				
Initials*	No.	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear				
n.	BA	WO-96/22786	08-01-1996	TAKEDA CHEMICAL					
	ŀ			INDUSTRIES, LTD.	<u> </u>				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicants unique citation designation number (optional): ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				<i>.</i>
Examiner Signature	1/0	P 14	Date Considered	8/10/107
			Techniquida	979/11

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection

Sub	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/749122-Conf. #3280	
11	IFORMATIC	N DI	SCLOSURE	Filing Date	December 30, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Richard L. BOYD	
				Art Unit	1645 /632	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned Mustani, 1A	
Sheet	1	of	1	Attorney Docket Number	0286336.00153US1/NOR-014CP4	

	U.S. PATENT DOCUMENTS							
Examiner	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where			
Initials*		Number-Kind Code ² (# known)			Relevant Passages or Relevant Figures Appear			
m	AA*	US-4,049,805	09-20-1977	Strade				
ON	AB*	US-5,759,551	06-02-1998	Ladd et al.				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
6.7	ВА	EP-0882736A1	12-09-1998	LABORATORIE THERAMEX, S.A.					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.usplo.gog or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
DA	CA	Gojo et al., Gene Therapy and Transplantation, (2000), Vol. 69, pp. 1-9.	
	СВ	Ross et al., "Gene Therapy in the United States: A Five-Year Status Report," Human Gene Therapy, 1996, pp. 1781-1790, Vol. 7.	
	C	Belhadj et al., "Hepatosplenic gamma-delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report of a Series of 21 Patients," Blood, 2003, pp. 4261-4269, Vol. 102.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	Wan	Date Considered	8/1967
	- 		

¹Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/749,122-Conf. #3280 INFORMATION DISCLOSURE Filing Date December 30, 2003 STATEMENT BY APPLICANT First Named Inventor Richard L. BOYD Art Unit 1632 (Use as many sheets as necessary) Not Yet Assigned Examiner Name Sheet of 1 0286336.00153US1 / NOR-0140P4

Attomey Docket Number

U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				

		FOREIG	SN PATENT I	DOCUMENTS		
Examiner Initials*	Cite	Foreign Patent Document	Publication Date n) MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	No.1	Country Code ³ -Number ⁴ -Kind Code ⁸ (# known)		Applicant of Cited Document		Τ٥

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
01	CA	HARRISON, "The Prospect of Vaccination to Prevent Type 1 Diabetes", Human Vaccines, (4):143-150 (2005)				
	СВ	TIAN, et al., "Recombinant Human Growth Hormone Promotes Hematopoietic Reconstitution after Syngeneic Bone Marrow Transplantation in Mice", Stem Cells, 16:193-199 (1998)				
	CC	VINCENT, et al., "Autoimmune Channelopathies and Related Neurological Disorders", Neuron, 52:123-138 (2006)				
V	CD	XIAO, et al., "Tolerogenic Dendritic Cells: The Ins and Outs of Outcome", J. Immunother, 29(5):465-471 (2006)				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	Verse		Date Considered	8/10/07
		7		

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.